title: Use of (99m)Tc-doxorubicin scintigraphy in females with breast cancer: a pilot study.
abstract: OBJECTIVE
  Doxorubicin (Eurofarma, São Paulo, Brazil) is an antitumour agent widely used in the treatment of breast cancer and can be used for tumour tracking when labelled with a radionuclide. Here, we present the results obtained with technetium-99m ((99m)Tc)-doxorubicin, using the direct method, to evaluate its uptake in breast cancer.
  
  
  METHODS
  Four females with confirmed breast carcinoma diagnosis and breast image reporting and data system Category 5 on mammography underwent whole-body and thorax single-photon emission CT/CT imaging 1 and 3 h after (99m)Tc-doxorubicin administration.
  
  
  RESULTS
  We observed increased uptake in breast carcinoma lesions and elimination via renal and hepatic pathways.
  
  
  CONCLUSIONS
  These preliminary results suggest that (99m)Tc-doxorubicin may be a promising radiopharmaceutical for the evaluation of patients with breast cancer. Further studies are ongoing.
  
  
  CONCLUSIONS
  To our knowledge, this is the first study to evaluate the use of a directly labelled doxorubicin tracer in humans. (99m)Tc-doxorubicin could provide information on the response of tumours to doxorubicin.
authors.affiliation: 1 Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: F I
authors.initials: FI
authors.lastname: Araujo
authors.affiliation: 2 Nuclear Medicine Section, National Cancer Institute, Rio de Janeiro, Brazil.
authors.forename: F P P
authors.initials: FP
authors.lastname: Proença
authors.affiliation: 3 Coordination of Clinical Research, National Cancer Institute, Rio de Janeiro, Brazil.
authors.forename: C G
authors.initials: CG
authors.lastname: Ferreira
authors.affiliation: 4 Division of Clinical Oncology, National Cancer Institute, Rio de Janeiro, Brazil.
authors.forename: S C
authors.initials: SC
authors.lastname: Ventilari
authors.affiliation: 2 Nuclear Medicine Section, National Cancer Institute, Rio de Janeiro, Brazil.
authors.forename: P H
authors.initials: PH
authors.lastname: Rosado de Castro
authors.affiliation: 3 Coordination of Clinical Research, National Cancer Institute, Rio de Janeiro, Brazil.
authors.forename: R D
authors.initials: RD
authors.lastname: Moreira
authors.affiliation: 1 Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: L M B
authors.initials: LM
authors.lastname: Fonseca
authors.affiliation: 1 Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: S A L
authors.initials: SA
authors.lastname: Souza
authors.affiliation: 1 Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: B
authors.initials: B
authors.lastname: Gutfilen
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000000981:diagnostic imaging*; D018270:Carcinoma, Ductal, Breast / Q000000981:diagnostic imaging*; D018275:Carcinoma, Lobular / Q000000981:diagnostic imaging*; D004317:Doxorubicin; D005260:Female; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013667:Technetium
chemical_list: D019275:Radiopharmaceuticals; D013667:Technetium; D004317:Doxorubicin